中国全科医学 ›› 2021, Vol. 24 ›› Issue (20): 2501-2507.DOI: 10.12114/j.issn.1007-9572.2021.00.595
所属专题: 指南/共识最新文章合辑; 高血压最新文章合辑
• 专题研究 • 下一篇
高血压心率管理多学科共识组
出版日期:
2021-07-15
发布日期:
2021-07-15
Published:
2021-07-15
Online:
2021-07-15
摘要: 心率增快是高血压常见的一种临床表型。多项研究显示,心率增快很可能是一项重要的心血管危险因素,伴随着增高的心血管事件发生率和死亡风险。心率增快的不利影响还涉及与高血压密切相关的多种内分泌、肾脏和神经内科疾病,心率管理需要多学科临床医生共同参与。因此,高血压心率管理多学科共识组组织心血管、内分泌、肾脏、神经、药学和循证医学等领域的专家,结合国内外最新且重要的循证资料,制定了《中国高血压患者心率管理多学科专家共识(2021年版)》。该共识阐述了高血压患者心率测量的方法、心率增快的原因和机制、心率增快伴随不利后果的临床证据、心率增快的干预方法以及高血压合并10种特殊疾病的心率管理。共识建议将静息心率>80 次/min作为高血压患者心率干预的切点,干预方法包括改善不良生活方式和使用兼有减慢心率作用的降压药物(首选选择性β1-受体阻滞剂)。共识还提出了简单实用的8条临床建议,以期为各学科医生针对不同类型高血压患者进行心率管理提供指导意见。
[1]MORCET J F,SAFAR M,THOMAS F,et al.Associations between heart rate and other risk factors in a large French population[J].J Hypertens,1999,17(12 Pt 1):1671-1676.DOI:10.1097/00004872-199917120-00003.
[2]孙宁玲,霍勇,黄峻.中国高血压患者心率现状调查[J].中华高血压杂志,2015,23(10):934-939.DOI:10.16439/j.cnki.1673-7245.2015.10.013.
SUN N L,HUO Y,HUANG J.The current status of heart rate in Chinese hypertensive patients[J].Chin J Hypertens,2015,23(10):934-939.DOI:10.16439/j.cnki.1673-7245.2015.10.013.
[3]PALATINI P.Role of elevated heart rate in the development of cardiovascular disease in hypertension[J].Hypertension,2011,58(5):745-750.DOI:10.1161/hypertensionaha.111.173104.
[4]施仲伟,冯颖青,林金秀,等.高血压患者心率管理中国专家共识[J].中国医学前沿杂志(电子版),2017,9(8):29-36.DOI:10.12037/YXQY.2017.08-06.
[5]ZHANG M,HAN C Y,WANG C J,et al.Association of resting heart rate and cardiovascular disease mortality in hypertensive and normotensive rural Chinese[J].J Cardiol,2017,69(5):779-784.DOI:10.1016/j.jjcc.2016.07.015.
[6]ZHAO M X,ZHAO Q H,ZHENG M Y,et al.Effect of resting heart rate on the risk of all-cause death in Chinese patients with hypertension:analysis of the Kailuan follow-up study[J].BMJ Open,2020,10(3):e032699.DOI:10.1136/bmjopen-2019-032699.
[7]PALATINI P,ROSEI E A,CASIGLIA E,et al.Management of the hypertensive patient with elevated heart rate:Statement of the Second Consensus Conference endorsed by the European Society of Hypertension[J].J Hypertens,2016,34(5):813-821.DOI:10.1097/HJH.0000000000000865.
[8]ALBANESE M,NEOFYTOU M,OUARRAK T,et al.Evaluation of heart rate measurements in clinical studies:a prospective cohort study in patients with heart disease[J].Eur J Clin Pharmacol,2016,72(7):789-795.DOI:10.1007/s00228-016-2046-9.
[9]HOZAWA A,OHKUBO T,KIKUYA M,et al.Prognostic value of home heart rate for cardiovascular mortality in the general population:the Ohasama study[J].Am J Hypertens,2004,17(11 Pt 1):1005-1010.DOI:10.1016/j.amjhyper.2004.06.019.
[10]PALATINI P,REBOLDI G,BEILIN L J,et al.Predictive value of night-time heart rate for cardiovascular events in hypertension.The ABP-International study[J].Int J Cardiol,2013,168(2):1490-1495.DOI:10.1016/j.ijcard.2012.12.103.
[11]PALATINI P,THIJS L,STAESSEN J A,et al.Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension[J].Arch Intern Med,2002,162(20):2313-2321.DOI:10.1001/archinte.162.20.2313.
[12]JOHANSEN C D,OLSEN R H,PEDERSEN L R,et al.Resting,night-time,and 24 h heart rate as markers of cardiovascular risk in middle-aged and elderly men and women with no apparent heart disease[J].Eur Heart J,2013,34(23):1732-1739.DOI:10.1093/eurheartj/ehs449.
[13]DE RIDDER B,VAN ROMPAEY B,KAMPEN J K,et al.Smartphone apps using photoplethysmography for heart rate monitoring:meta-analysis[J].JMIR Cardio,2018,2(1):e4.DOI:10.2196/cardio.8802.
[14]ETIWY M,AKHRASS Z,GILLINOV L,et al.Accuracy of wearable heart rate monitors in cardiac rehabilitation[J].Cardiovasc Diagn Ther,2019,9(3):262-271.DOI:10.21037/cdt.2019.04.08.
[15]ROBINSON L E,HOLT T A,REES K,et al.Effects of exenatide and liraglutide on heart rate,blood pressure and body weight:systematic review and meta-analysis[J].BMJ Open,2013,3(1):e001986.DOI:10.1136/bmjopen-2012-001986.
[16]LORENZ M,LAWSON F,OWENS D,et al.Differential effects of glucagon-like peptide-1 receptor agonists on heart rate[J].Cardiovasc Diabetol,2017,16(1):6.DOI:10.1186/s12933-016-0490-6.
[17]ESLER M,LAMBERT G,ESLER D,et al.Evaluation of elevated heart rate as a sympathetic nervous system biomarker in essential hypertension[J].J Hypertens,2020,38(8):1488-1495.DOI:10.1097/hjh.0000000000002407.
[18]CUSTODIS F,SCHIRMER S H,BAUMHÄKEL M,et al.Vascular pathophysiology in response to increased heart rate[J].J Am Coll Cardiol,2010,56(24):1973-1983.DOI:10.1016/j.jacc.2010.09.014.
[19]TADIC M,CUSPIDI C,GRASSI G.Heart rate as a predictor of cardiovascular risk[J].Eur J Clin Investig,2018,48(3):e12892.DOI:10.1111/eci.12892.
[20]INOUE T,ISEKI K,ISEKI C,et al.Higher heart rate predicts the risk of developing hypertension in a normotensive screened cohort[J].Circ J,2007,71(11):1755-1760.DOI:10.1253/circj.71.1755.
[21]PALATINI P,DORIGATTI F,ZAETTA V,et al.Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension:the HARVEST Study[J].J Hypertens,2006,24(9):1873-1880.DOI:10.1097/01.hjh.0000242413.96277.5b.
[22]BENETOS A,ADAMOPOULOS C,BUREAU J M,et al.Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period[J].Circulation,2002,105(10):1202-1207.DOI:10.1161/hc1002.105135.
[23]BÖHM M,REIL J C,DANCHIN N,et al.Association of heart rate with microalbuminuria in cardiovascular risk patients:data from I-SEARCH[J].J Hypertens,2008,26(1):18-25.DOI:10.1097/HJH.0b013e3282f05c8a.
[24]WANG A X,LIU X X,GUO X H,et al.Resting heart rate and risk of hypertension:results of the Kailuan cohort study[J].J Hypertens,2014,32(8):1600-1605.DOI:10.1097/HJH.0000000000000230.
[25]ZHAO Y,QIN P,SUN H H,et al.Resting heart rate and its dynamic change and the risk of hypertension:the Rural Chinese Cohort Study[J].J Hum Hypertens,2020,34(7):528-535.DOI:10.1038/s41371-019-0259-y.
[26]KING D E,EVERETT C J,MAINOUS A G,et al.Long-term prognostic value of resting heart rate in subjects with prehypertension[J].Am J Hypertens,2006,19(8):796-800.DOI:10.1016/j.amjhyper.2006.01.019.
[27]GILLMAN M W,KANNEL W B,BELANGER A,et al.Influence of heart rate on mortality among persons with hypertension:the Framingham Study[J].Am Heart J,1993,125(4):1148-1154.DOI:10.1016/0002-8703(93)90128-v.
[28]BENETOS A,RUDNICHI A,THOMAS F,et al.Influence of heart rate on mortality in a French population:role of age,gender,and blood pressure[J].Hypertension,1999,33(1):44-52.DOI:10.1161/01.hyp.33.1.44.
[29]THOMAS F,BEAN K,PROVOST J C,et al.Combined effects of heart rate and pulse pressure on cardiovascular mortality according to age[J].J Hypertens,2001,19(5):863-869.DOI:10.1097/00004872-200105000-00005.
[30]PAUL L,HASTIE C E,LI W S,et al.Resting heart rate pattern during follow-up and mortality in hypertensive patients[J].Hypertension,2010,55(2):567-574.DOI:10.1161/hypertensionaha.109.144808.
[31]SAXENA A,MINTON D,LEE D C,et al.Protective role of resting heart rate on all-cause and cardiovascular disease mortality[J].Mayo Clin Proc,2013,88(12):1420-1426.DOI:10.1016/j.mayocp.2013.09.011.
[32]KOLLOCH R,LEGLER U F,CHAMPION A,et al.Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease:findings from the INternational VErapamil-SR/trandolapril STudy(INVEST)[J].Eur Heart J,2008,29(10):1327-1334.DOI:10.1093/eurheartj/ehn123.
[33]OKIN P M,KJELDSEN S E,JULIUS S,et al.All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy[J].Eur Heart J,2010,31(18):2271-2279.DOI:10.1093/eurheartj/ehq225.
[34]POULTER N R,DOBSON J E,SEVER P S,et al.Baseline heart rate,antihypertensive treatment,and prevention of cardiovascular outcomes in ASCOT(Anglo-Scandinavian Cardiac Outcomes Trial)[J].J Am Coll Cardiol,2009,54(13):1154-1161.DOI:10.1016/j.jacc.2009.04.087.
[35]JULIUS S,PALATINI P,KJELDSEN S E,et al.Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension[J].Am J Cardiol,2012,109(5):685-692.DOI:10.1016/j.amjcard.2011.10.025.
[36]LONN E M,RAMBIHAR S,GAO P,et al.Heart rate is associated with increased risk of major cardiovascular events,cardiovascular and all-cause death in patients with stable chronic cardiovascular disease:an analysis of ONTARGET/TRANSCEND[J].Clin Res Cardiol,2014,103(2):149-159.DOI:10.1007/s00392-013-0644-4.
[37]KOSSMANN C E.The normal electrocardiogram[J].Circulation,1953,8(6):920-936.DOI:10.1161/01.cir.8.6.920.
[38]SPODICK D H.Normal sinus heart rate:appropriate rate thresholds for sinus tachycardia and bradycardia[J].South Med J,1996,89(7):666-667.DOI:10.1097/00007611-199607000-00003.
[39]RYU M,BAYASGALAN G,KIMM H,et al.Association of resting heart rate and hypertension stages on all-cause and cardiovascular mortality among elderly Koreans:the Kangwha Cohort Study[J].J Geriatr Cardiol,2016,13(7):573-579.DOI:10.11909/j.issn.1671-5411.2016.07.003.
[40]LI X,WANG Z W,WANG X,et al.Relationship between heart rate and blood pressure level among community hypertensive patients[J].Int J Cardiol,2011,152:S28.DOI:10.1016/j.ijcard.2011.08.557.
[41]GRASSI G,QUARTI-TREVANO F,SERAVALLE G,et al.Association between the European society of cardiology/European society of hypertension heart rate thresholds for cardiovascular risk and neuroadrenergic markers[J].Hypertension,2020,76(2):577-582.DOI:10.1161/HYPERTENSIONAHA.120.14804.
[42]WIYSONGE C S,BRADLEY H A,VOLMINK J,et al.Beta-blockers for hypertension[J].Cochrane Database Syst Rev,2017,1:CD002003.DOI:10.1002/14651858.CD002003.pub2.
[43]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018 [J].中华心血管病杂志,2018,46(10):760-789.DOI:10.3760/cma.j.issn.0253-3758.2018.10.004.
[44]国家卫生计生委合理用药专家委员会,中国药师协会.心力衰竭合理用药指南(第2版)[J].中国医学前沿杂志(电子版),2019,11(7):1-78.DOI:10.12037/YXQY.2019.07-01.
[45]PONIKOWSKI P,VOORS A A,ANKER S D,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J].Eur Heart J,2016,37(27):2129-2200.DOI:10.1093/eurheartj/ehw128.
[46]YANCY C W,JESSUP M,BOZKURT B,et al.2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America[J].Circulation,2017,136(6):e137-161.DOI:10.1161/CIR.0000000000000509.
[47]MEYER M,LEWINTER M M.Heart rate and heart failure with preserved ejection fraction:time to slow β-blocker use?[J].Circ Heart Fail,2019,12(8):e006213.DOI:10.1161/CIRCHEARTFAILURE.119.006213.
[48]BRUBAKER P H,KITZMAN D W.Chronotropic incompetence:causes,consequences,and management[J].Circulation,2011,123(9):1010-1020.DOI:10.1161/circulationaha.110.940577.
[49]MARTIN N,MANOHARAN K,THOMAS J,et al.Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction[J].Cochrane Database Syst Rev,2018,6:CD012721.DOI:10.1002/14651858.CD012721.pub2.
[50]黄从新,张澍,黄德嘉,等.心房颤动:目前的认识和治疗的建议-2018[J].中国心脏起搏与心电生理杂志,2018,32(4):315-368.DOI:10.13333/j.cnki.cjcpe.2018.04.001.
[51]中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.心房颤动基层诊疗指南(2019年)[J].中华全科医师杂志,2020,19(6):465-473.DOI:10.3760/cma.j.cn114798-20191118-00838.
[52]HINDRICKS G,POTPARA T,DAGRES N,et al.2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS)[J].Eur Heart J,2021,42(5):373-498.DOI:10.1093/eurheartj/ehaa612.
[53]中华医学会心血管病学分会介入心脏病学组,中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2018,46(9):680-694.DOI:10.3760/cma.j.issn.0253-3758.2018.09.004.
[54]KNUUTI J,WIJNS W,SARASTE A,et al.2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J].Eur Heart J,2020,41(3):407-477.DOI:10.1093/eurheartj/ehz425.
[55]BORER J S,DEEDWANIA P C,KIM J B,et al.Benefits of heart rate slowing with ivabradine in patients with systolic heart failure and coronary artery disease[J].Am J Cardiol,2016,118(12):1948-1953.DOI:10.1016/j.amjcard.2016.08.089.
[56]中国心胸血管麻醉学会,北京高血压防治协会.围术期高血压管理中国专家共识[J].临床麻醉学杂志,2016,32(3):295-297.
[57]HIRATZKA L F,BAKRIS G L,BECKMAN J A,et al.2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease:a report of the American college of cardiology foundation/American heart association task force on practice guidelines,American association for thoracic surgery,American college of radiology,American stroke association,society of cardiovascular anesthesiologists,society for cardiovascular angiography and interventions,society of interventional radiology,society of thoracic surgeons,and society for vascular medicine[J].Circulation,2010,121(13):e266-369.DOI:10.1161/CIR.0b013e3181d4739e.
[58]ERBEL R,ABOYANS V,BOILEAU C,et al.2014 ESC Guidelines on the diagnosis and treatment of aortic diseases:document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult.The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology(ESC)[J].Eur Heart J,2014,35(41):2873-2926.DOI:10.1093/eurheartj/ehu281.
[59]ROSS D S,BURCH H B,COOPER D S,et al.2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J].Thyroid,2016,26(10):1343-1421.DOI:10.1089/thy.2016.0229.
[60]中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志,2007,46(10):876-882.DOI:10.3760/j.issn:0578-1426.2007.10.035.
[61]HILLIS G S,WOODWARD M,RODGERS A,et al.Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus[J].Diabetologia,2012,55(5):1283-1290.DOI:10.1007/s00125-012-2471-y.
[62]PRASADA S,OSWALT C,YEBOAH P,et al.Heart rate is an independent predictor of all-cause mortality in individuals with type 2 diabetes:the diabetes heart study[J].World J Diabetes,2018,9(1):33-39.DOI:10.4239/wjd.v9.i1.33.
[63]SPALLONE V,ZIEGLER D,FREEMAN R,et al.Cardiovascular autonomic neuropathy in diabetes:clinical impact,assessment,diagnosis,and management[J].Diabetes Metab Res Rev,2011,27(7):639-653.DOI:10.1002/dmrr.1239.
[64]BÖHM M,SCHUMACHER H,TEO K K,et al.Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials[J].Eur Heart J,2020,41(2):231-238.DOI:10.1093/eurheartj/ehy808.
[65]中华医学会内分泌学分会.嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)[J].中华内分泌代谢杂志,2020,36(9):737-750.DOI:10.3760/cma.j.cn311282-20200629-00482.
[66]LENDERS J W,DUH Q Y,EISENHOFER G,et al.Pheochromocytoma and paraganglioma:an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab,2014,99(6):1915-1942.DOI:10.1210/jc.2014-1498.
[67]GRASSI G,BIFFI A,SERAVALLE G,et al.Sympathetic neural overdrive in the obese and overweight state[J].Hypertension,2019,74(2):349-358.DOI:10.1161/HYPERTENSIONAHA.119.12885.
[68]YAN Y L,ZHANG Y,YANG Q,et al.Association between resting heart rate and hypertension in Chinese with different waist-to-height ratio:a population-based cross-sectional study[J].J Am Soc Hypertens,2018,12(12):e93-101.DOI:10.1016/j.jash.2018.08.005.
[69]JORDAN J,YUMUK V,SCHLAICH M,et al.Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension:obesity and difficult to treat arterial hypertension[J].J Hypertens,2012,30(6):1047-1055.DOI:10.1097/hjh.0b013e3283537347.
[70]中华医学会心血管病学分会高血压学组.肥胖相关性高血压管理的中国专家共识[J].中华心血管病杂志,2016,44(3):212-219.
[71]KAUR J,YOUNG B E,FADEL P J.Sympathetic overactivity in chronic kidney disease:consequences and mechanisms[J].Int J Mol Sci,2017,18(8):1682.DOI:10.3390/ijms18081682.
[72]PUGH D,GALLACHER P J,DHAUN N.Management of hypertension in chronic kidney disease[J].Drugs,2019,79(4):365-379.DOI:10.1007/s40265-019-1064-1.
[73]FOLEY R N,HERZOG C A,COLLINS A J,et al.Blood pressure and long-term mortality in United States hemodialysis patients:USRDS Waves 3 and 4 Study[J].Kidney Int,2002,62(5):1784-1790.DOI:10.1046/j.1523-1755.2002.00636.x.
[74]ABBOTT K C,TRESPALACIOS F C,AGODOA L Y,et al.Beta-Blocker use in long-term dialysis patients:association with hospitalized heart failure and mortality[J].Arch Intern Med,2004,164(22):2465-2471.DOI:10.1001/archinte.164.22.2465.
[75]SHIREMAN T I,MAHNKEN J D,PHADNIS M A,et al.Effectiveness comparison of cardio-selective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease:a retrospective cohort study[J].BMC Cardiovasc Disord,2016,16:60.DOI:10.1186/s12872-016-0233-3.
[76]第八届中华肾脏病学会慢性肾脏病高血压治疗专家协作组.α/β受体阻滞剂在慢性肾脏病高血压治疗中的实践指南[J].中华医学杂志,2013,93(48):3812-3816.DOI:10.3760/cma.j.issn.0376-2491.2013.48.002.
[77]BÖHM M,COTTON D,FOSTER L,et al.Impact of resting heart rate on mortality,disability and cognitive decline in patients after ischaemic stroke[J].Eur Heart J,2012,33(22):2804-2812.DOI:10.1093/eurheartj/ehs250.
[78]PALATINI P,BENETOS A,GRASSI G,et al.Identification and management of the hypertensive patient with elevated heart rate:statement of a European Society of Hypertension Consensus Meeting[J].J Hypertens,2006,24(4):603-610.DOI:10.1097/01.hjh.0000217838.49842.1e.
[79]WILLIAMS B,MANCIA G,SPIERING W,et al.2018 ESC/ESH Guidelines for the management of arterial hypertension[J].Eur Heart J,2018,39(33):3021-3104.DOI:10.1093/eurheartj/ehy339.
[80]DALAL J,DASBISWAS A,SATHYAMURTHY I,et al.Heart rate in hypertension:review and expert opinion[J].Int J Hypertens,2019,2019:2087064.DOI:10.1155/2019/2087064.
[81]UNGER T,BORGHI C,CHARCHAR F,et al.2020 International Society of Hypertension global hypertension practice guidelines[J].J Hypertens,2020,38(6):982-1004.DOI:10.1097/hjh.0000000000002453.
|
[1] | 吴文俊, 卫靖靖, 李雪, 任红杰, 于瑞, 彭广操, 朱明军. 基于隐结构模型结合关联规则分析冠心病合并高血压的方药规律[J]. 中国全科医学, 2025, 28(30): 3787-3795. |
[2] | 白佳欣, 程玉, 周伊恒, 刘力滴, 杨荣, 姚易, 袁波, 张永刚, 雷弋, 曾锐, 贾禹, 廖晓阳. 《早发性高血压的评估与治疗:英国和爱尔兰高血压协会立场声明》对中国早发性高血压临床管理的建议[J]. 中国全科医学, 2025, 28(30): 3741-3746. |
[3] | 秦邦国, 孙瑾, 李曼, 邱娇娇, 程柏凯, 朱平, 王曙霞. 农村高血压人群非高密度脂蛋白胆固醇与高密度脂蛋白胆固醇比值与左心室肥厚的关系研究[J]. 中国全科医学, 2025, 28(30): 3753-3760. |
[4] | 韩笑, 李奇遇, 葛蒲, 范思园, 刘迪玥, 吴一波, 张清霜. 高血压患者行为生活方式对生命质量的影响研究[J]. 中国全科医学, 2025, 28(26): 3248-3258. |
[5] | 余孜孜, 刘杜丽, 李熙敏, 阮春怡, 尹向阳, 蔡乐. 农村高血压患病和自我管理现状及影响因素研究[J]. 中国全科医学, 2025, 28(25): 3137-3143. |
[6] | 唐尚锋, 黄阳珍, 潘阳阳, 郑妍惜, 熊忠宝, 张康康, 宋佳, 魏艺琳, 王春盈, 董衡, 陈蔓维, 卿华. 高血压基层医防融合服务规范[J]. 中国全科医学, 2025, 28(25): 3089-3095. |
[7] | 魏云鸿, 杨莉, 王玉路, 叶秋芳, 代安妮, 何燕. 肥胖相关性高血压患者不同运动阶段心肺功能的研究[J]. 中国全科医学, 2025, 28(24): 2972-2978. |
[8] | 何金玉, 朱丽都孜·解思思别克, 张宁, 刘民, 梁万年. 我国规范化管理高血压患者血压控制及影响因素研究的现状、挑战与未来展望[J]. 中国全科医学, 2025, 28(24): 2968-2971. |
[9] | 陈友兰, 蓝彦琦, 吴阿华, 张海霞, 黄健康, 郭志南. "三师共管"家庭医生签约服务对老年高血压患者的健康管理效果研究[J]. 中国全科医学, 2025, 28(22): 2769-2775. |
[10] | 郝爱华, 曾子莹, 金爱琼, 唐玲玲, 郑梓悫, 马景泰, 赵建国, 曾韦霖, 肖建鹏, 聂辉, 杨颖. 老年高血压患者可避免住院的影响因素研究[J]. 中国全科医学, 2025, 28(19): 2370-2375. |
[11] | 郭翔云, 章轶立, 李婷, 冯天笑, 李玲慧, 孙凯, 王旭, 秦晓宽, 田金洲, 朱立国, 魏戌. 骨健康重点病种流行趋势及影响因素分析[J]. 中国全科医学, 2025, 28(19): 2346-2353. |
[12] | 朱立国. 夯实基层骨健康服务根基 助力推进健康中国计划[J]. 中国全科医学, 2025, 28(19): 2345-2345. |
[13] | 王志军, 张士博, 刘杰, 李东琦, 郑美佳, 周建芝. 高血压患者三酰甘油葡萄糖体质量指数与夜间高血压的相关性分析[J]. 中国全科医学, 2025, 28(18): 2212-2221. |
[14] | 张志东, 金华, 胡继宏, 蒋露, 王莉, 龙开冲, 张荣华. 1990—2021年中国高血压肾病发病率和死亡率变化趋势分析及预测研究[J]. 中国全科医学, 2025, 28(18): 2262-2269. |
[15] | 何燕, 崔赛仙, 胡阳, 倪晴, 甘露路, 刘茜, 代安妮, 刘师节, 杨莉. 阻塞性睡眠呼吸暂停相关高血压患者尿钠排泄及影响因素研究[J]. 中国全科医学, 2025, 28(18): 2222-2227. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||